< Back to search trials

A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma

  • Clinicaltrials.gov #: NCT03675737
  • Acronym: KEYNOTE-859
  • Tumor Type: Gastrointestinal
  • Tumor Subtype: Gastric/Stomach Cancer
  • Tumor Stage: Metastatic (1st, 2nd, 3rd, or 4th line)
  • Type of Treatment: